BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

VentriPoint Diagnostics Announces European CE Mark Approval of Critical Cardiac Diagnostic System


12/10/2009 6:27:09 AM

Bookmark and Share

SEATTLE, WASHINGTON--(Marketwire - 12/10/09) - VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX-V:VPT - News) is pleased to announce that it has received approval to CE Mark its VentriPoint Medical System (VMS) which generates critical heart measurements from 2D ultrasounds in a rapid, accurate and inexpensive manner not currently available. Rapid and accurate right ventricle measurements is essential for assessment of patients with cardiovascular disease. As reported in a recent Journal of American Heart Association, Circulation, and confirmed in other publications, /"many studies have demonstrated the prognostic value of RV function in cardiovascular disease".

The CE Mark enables VentriPoint to sell its VentriPoint Medical System broadly around the globe. The device has already received Health Canada clearance and the submission to the FDA for US approval was recently filed.

"Accomplishing CE Mark approval is the latest step in what continues to be the steady advance toward commercializing our VentriPoint Medical System," said Joseph Ashley, CEO of VentriPoint. "It's also an important milestone in our strategy for reaching the worldwide market for critical heart monitoring, which is estimated to be more than $5 billion annually. We are encouraged by our progress and look forward to announcing other achievements in the near future."

Mr. Ashley said that efforts to commercialize the VentriPoint Medical System in Europe will benefit from having three highly esteemed European investigators as co-authors of the recently announced manuscript accepted for publication by the peer reviewed American Journal of Cardiology. The Manuscript presented the exceptionally accurate and reproducible results of a multinational clinical validation study of the VentriPoint Medical System's Knowledge Based Reconstruction. The results agreed closely with true values for end-diastolic volume (r equals 0.993), end-systolic volume (r equals 0.992), and ejection fraction (EF; r equals 0.930). By using information produced from currently deployed 2D ultrasounds which are ubiquitous around the world, the VentriPoint Medical System will provide these critical results to medical professionals for less than $100/ study as compared to the expenditure of multiple $100 thousands for a new 3D ultrasound with recently published accuracies of 0.93, 0.92 and 0.72 (ED, ES and EF) or the even more expensive MRIs.

About VentriPoint Diagnostics Ltd.

VentriPoint creates diagnostic tools to monitor patients with heart disease - the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Medical System ("VMS") generates critical heart measurements in a rapid, accurate and inexpensive manner not currently available. Health Canada and Europe have granted licensed approval for the VMS breakthrough diagnostic tool which is based upon technology received by VentriPoint through its exclusive technology license with the University of Washington. The VMS, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease and pulmonary hypertension.

To receive press release, please email chris@chfir.com and mention VentriPoint in the Subject line.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: VentriPoint Diagnostics Ed Garth Chief Financial Officer (206) 283-0221, ext. 402 (206) 283-2309 (FAX) CHF Investor Relations Christopher Haldane Account Manager (416) 868-1079 ext.237 (416) 868-6198 (FAX)


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->